Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van de Putte, L B A
Right arrow Articles by Kupper, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van de Putte, L B A
Right arrow Articles by Kupper, H
Annals of the Rheumatic Diseases 2004;63:508-516
© 2004 by BMJ Publishing Group Ltd & European League Against Rheumatism


EXTENDED REPORT

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

L B A van de Putte 1, C Atkins 2, M Malaise 3, J Sany 4, A S Russell 5, P L C M van Riel 1, L Settas 6, J W Bijlsma 7, S Todesco 8, M Dougados 9, P Nash 10, P Emery 11, N Walter 12, M Kaul 12, S Fischkoff 13, H Kupper 12

1 University of Nijmegen, The Netherlands
2 Victoria, British Columbia, Canada
3 Service de Rhumatologie, Liege, Belgium
4 Hôpital Lapeyronie, Montpellier, France
5 University of Alberta Hospital, Edmonton, Alberta, Canada
6 AHEPA Hospital, Thessaloniki, Greece
7 UMC Utrecht, Utrecht, The Netherlands
8 Cattedra e Divisione di Reumatologia, Università di Padova, Padova, Italy
9 Service de Rhumatologie, Hôpital Cochin, Paris, France
10 Sixth Avenue Specialist Centre, Maroochydore, Australia
11 University of Leeds, Leeds, UK
12 Abbott GmbH & Co KG, Ludwigshafen, Germany
13 Abbott Laboratories, Parsippany, New Jersey, USA

Correspondence to:
Correspondence to:
Professor L B A van de Putte
University Medical Centre Nijmegen, Department of Rheumatology, PO Box 9101, 6500 HB Nijmegen, The Netherlands; annrheumdis.edoff{at}worldonline.nl

Objective: To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD treatment has failed.

Methods: In a 26 week, double blind, placebo controlled, phase III trial, 544 patients with RA were randomised to monotherapy with adalimumab 20 mg every other week, 20 mg weekly, 40 mg every other week, 40 mg weekly, or placebo. The primary efficacy end point was >=20% improvement in the ACR core criteria (ACR20 response). Secondary efficacy end points included ACR50, ACR70, EULAR responses, and the Disability Index of the Health Assessment Questionnaire (HAQ DI).

Results: After 26 weeks, patients treated with adalimumab 20 mg every other week, 20 mg weekly, 40 mg every other week, and 40 mg weekly had significantly better response rates than those treated with placebo: ACR20 (35.8%, 39.3%, 46.0%, 53.4%, respectively v 19.1%; p<=0.01); ACR50 (18.9%, 20.5%, 22.1%, 35.0% v 8.2%; p<=0.05); ACR70 (8.5%, 9.8%, 12.4%, 18.4% v 1.8%; p<=0.05). Moderate EULAR response rates were significantly greater with adalimumab than with placebo (41.5%, 48.2%, 55.8%, 63.1% v 26.4%; p<=0.05). Patients treated with adalimumab achieved better improvements in mean HAQ DI than those receiving placebo (–0.29, –0.39, –0.38, –0.49 v –0.07; p<=0.01). No significant differences were found between adalimumab and placebo treated patients for serious adverse events, serious infections, or malignancies. Injection site reaction occurred in 10.6% and 0.9% of adalimumab and placebo treated patients, respectively (p<=0.05).

Conclusion: Among patients with RA for whom previous DMARD treatment had failed, adalimumab monotherapy achieved significant, rapid, and sustained improvements in disease activity and improved physical function and was safe and well tolerated.


Keywords: adalimumab; disease modifying antirheumatic drugs; human monoclonal antibodies; monotherapy; rheumatoid arthritis; tumour necrosis factor {alpha}

Abbreviations: ACR, American College of Rheumatology; ANA, antinuclear antibody; CRP, C reactive protein; DAS, disease activity score; DMARDs, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ DI, Disability Index of the Health Assessment Questionnaire; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; TNF, tumour necrosis factor




This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
Y. Yazici, N. M. Adler, and H. Yazici
Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations
Rheumatology, July 1, 2008; 47(7): 1054 - 1057.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
J. M. Pocock, J. C. Vasconcelos, and A. J. K. Ostor
Assessment of anti-TNF-{alpha} efficacy in rheumatoid arthritis: is 3 months sufficient?
Rheumatology, July 1, 2008; 47(7): 1073 - 1076.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
D Aletaha, V Strand, J S Smolen, and M M Ward
Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results
Ann Rheum Dis, February 1, 2008; 67(2): 238 - 243.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22.
[Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
C. ALESSANDRI, R. SCRIVO, F. R. SPINELLI, F. CECCARELLI, L. MAGRINI, R. PRIORI, and G. VALESINI
Autoantibody Production in Anti-TNF-{alpha}-Treated Patients
Ann. N.Y. Acad. Sci., September 1, 2007; 1110(1): 319 - 329.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
W J Sandborn, S B Hanauer, P Rutgeerts, R N Fedorak, M Lukas, D G MacIntosh, R Panaccione, D Wolf, J D Kent, B Bittle, et al.
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
Gut, September 1, 2007; 56(9): 1232 - 1239.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
A. Brennan, N. Bansback, R. Nixon, J. Madan, M. Harrison, K. Watson, and D. Symmons
Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
Rheumatology, August 1, 2007; 46(8): 1345 - 1354.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
G. M Bartelds, C. A Wijbrandts, M. T Nurmohamed, S. Stapel, W. F Lems, L. Aarden, B. A C Dijkmans, P. P. Tak, and G. J. Wolbink
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Ann Rheum Dis, July 1, 2007; 66(7): 921 - 926.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
R. Nixon, N. Bansback, and A. Brennan
The efficacy of inhibiting tumour necrosis factor {alpha} and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons
Rheumatology, July 1, 2007; 46(7): 1140 - 1147.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
S. Bombardieri, A. A. Ruiz, P. Fardellone, P. Geusens, F. McKenna, K. Unnebrink, U. Oezer, S. Kary, H. Kupper, G. R. Burmester, et al.
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice
Rheumatology, July 1, 2007; 46(7): 1191 - 1199.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
G. R Burmester, X. Mariette, C. Montecucco, I. Monteagudo-Saez, M. Malaise, A. G Tzioufas, J. W J Bijlsma, K. Unnebrink, S. Kary, H. Kupper, et al.
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
Ann Rheum Dis, June 1, 2007; 66(6): 732 - 739.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
J. A G van Roon, S. A Y Hartgring, M. Wenting-van Wijk, K. M G Jacobs, P.-P. Tak, J. W J Bijlsma, and F. P J G Lafeber
Persistence of interleukin 7 activity and levels on tumour necrosis factor {alpha} blockade in patients with rheumatoid arthritis
Ann Rheum Dis, May 1, 2007; 66(5): 664 - 669.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
A. Kuek, B. L Hazleman, and A. J K Ostor
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Postgrad. Med. J., April 1, 2007; 83(978): 251 - 260.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Ophthalmol.Home page
S. Biester, C. Deuter, H. Michels, R. Haefner, J. Kuemmerle-Deschner, D. Doycheva, and M. Zierhut
Adalimumab in the therapy of uveitis in childhood
Br. J. Ophthalmol., March 1, 2007; 91(3): 319 - 324.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
C. Salliot, L. Gossec, A. Ruyssen-Witrand, M. Luc, M. Duclos, S. Guignard, and M. Dougados
Infections during tumour necrosis factor-{alpha} blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients
Rheumatology, February 1, 2007; 46(2): 327 - 334.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
Y Yazici and H Yazici
A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors
Ann Rheum Dis, January 1, 2007; 66(1): 124 - 127.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, P Emery, E C Keystone, M H Schiff, P L C M van Riel, M E Weinblatt, et al.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006
Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii2 - iii15.
[Full Text] [PDF]


Home page
Ann Rheum DisHome page
M S Heiberg, E Rodevand, K Mikkelsen, C Kaufmann, A Didriksen, P Mowinckel, and T K Kvien
Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study
Ann Rheum Dis, October 1, 2006; 65(10): 1379 - 1383.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D.L. Scott and G.H. Kingsley
Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis.
N. Engl. J. Med., August 17, 2006; 355(7): 704 - 712.
[Full Text] [PDF]


Home page
EDUCATION AND PRACTICEHome page
L. J McCann, L. R Wedderburn, and N. Hasson
JUVENILE IDIOPATHIC ARTHRITIS
Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep29 - ep36.
[Full Text] [PDF]


Home page
Ann Rheum DisHome page
R M Fleischmann, J Tesser, M H Schiff, J Schechtman, G-R Burmester, R Bennett, D Modafferi, L Zhou, D Bell, and B Appleton
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
Ann Rheum Dis, August 1, 2006; 65(8): 1006 - 1012.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
M H Schiff, G R Burmester, J D Kent, A L Pangan, H Kupper, S B Fitzpatrick, and C Donovan
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
Ann Rheum Dis, July 1, 2006; 65(7): 889 - 894.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
M E Weinblatt, E C Keystone, D E Furst, A F Kavanaugh, E K Chartash, and O G Segurado
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
Ann Rheum Dis, June 1, 2006; 65(6): 753 - 759.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
T. Bongartz, A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, and V. Montori
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
JAMA, May 17, 2006; 295(19): 2275 - 2285.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
D Aletaha and M M Ward
Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials
Ann Rheum Dis, February 1, 2006; 65(2): 227 - 233.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, et al.
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv2 - iv14.
[Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
A. N. Bennett, P. Peterson, A. Zain, J. Grumley, G. Panayi, and B. Kirkham
Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure
Rheumatology, August 1, 2005; 44(8): 1026 - 1031.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
D P M Symmons
Anti-tumour necrosis factor {alpha} therapy: can we afford it?
Ann Rheum Dis, July 1, 2005; 64(7): 969 - 970.
[Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
J. ZWERINA, K. REDLICH, G. SCHETT, and J. S. SMOLEN
Pathogenesis of Rheumatoid Arthritis: Targeting Cytokines
Ann. N.Y. Acad. Sci., June 1, 2005; 1051(1): 716 - 729.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
S. Rott and U. Mrowietz
Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies
BMJ, March 26, 2005; 330(7493): 716 - 720.
[Full Text] [PDF]


Home page
Evid. Based Med.Home page
Other articles noted
Evid. Based Med., September 1, 2004; 9(5): e5 - e5.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 BMJ Publishing Group Ltd & European League Against Rheumatism